ClassID:

94634

C07D257/02 - CPC Classification

Classification description:

Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Sub-classes:
Recent Application in this class:
#1
20260115291
2026-04-30

AZOBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THERAPEUTIC TREATMENT ASSOCIATED WITH IONIZING RADIATIONS

#2
20260103447
2026-04-16

METHODS FOR PREPARING PSMA CONJUGATES

#3
20260015331
2026-01-15

Process Or The Preparation Of A Gadolinium Contrast Agent

#4
20260007785
2026-01-08

USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#5
20260007784
2026-01-08

USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#6
20250376451
2025-12-11

NOVEL PROCESS FOR THE PREPARATION OF MACROCYCLIC CHELANT 2,2',2''-(10-(2-HYDROXYPROPYL)-1,4,7,10-TETRA AZACYCLODODECANE- 1,4,7-TRIYL) TRIACETIC ACID AND IT’S COMPLEXES WITH PARAMAGNETIC METAL IONS

#7
20250319212
2025-10-16

GADOLINIUM-BASED COMPOUND, AND MRI CONTRAST AGENT INCLUDING SAME

#8
20250230135
2025-07-17

METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

#9
20250223243
2025-07-10

SYNTHESIZING AN ORGANIC HIGH EXPLOSIVE IN A FLOW REACTOR

#10
20250213718
2025-07-03

LIPIDS FOR NUCLEIC ACID DELIVERY

#11
20250213698
2025-07-03

BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS

#12
20250206706
2025-06-26

A METHOD OF PRODUCING EXPLOSIVE HMX BY FLOW SYNETHESIS

#13
20250195700
2025-06-19

PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER

#14
20250179034
2025-06-05

IONIZABLE LIPIDS AND COMPOSITIONS COMPRISING SAME

#15
20250136560
2025-05-01

PROCESS TO PRODUCE HEXAHYDRO-1,3,5-TRINITRO-1,3,5-TRIAZINE AND OCTAHYDRO-1,3,5,7-TETRANITRO-1,3,5,7-TETRAZOCINE WITH DIRECT RECYCLE OF SPENT ACID

#16
20250114485
2025-04-10

GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING

#17
20240408249
2024-12-12

EGFRVIII-TARGETED COMPOUNDS AND USES THEREOF

#18
20240382631
2024-11-21

USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#19
20240350680
2024-10-24

LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#20
20240335571
2024-10-10

PRE-TARGETING STRATEGIES FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPY

#21
20240300906
2024-09-12

PROCESS FOR PRODUCING HEXAHYDRO 1,3,5-TRINITRO-1,3,5-TRIAZINE AND OCTAHYDRO-1,3,5,7-TETRANITRO-1,3,5,7-TETRAZOCINE

#22
20240299599
2024-09-12

DIMERIZATION STRATEGIES AND COMPOUNDS FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPY

#23
20240285808
2024-08-29

MOLECULAR PROBES FOR IN VIVO DETECTION OF ALDEHYDES

#24
20240269343
2024-08-15

USE OF IMMUNE MODULATORS TO IMPROVE NERVE REGENERATION

#25
20240254092
2024-08-01

BIFUNCTIONAL CHELATORS AND CONJUGATES

#26
20240228445
2024-07-11

PROCESS FOR PRODUCING HEXAHYDRO 1,3,5-TRINITRO-1,3,5-TRIAZINE AND OCTAHYDRO-1,3,5,7-TETRANITRO-1,3,5,7-TETRAZOCINE

#27
20240226302
2024-07-11

BIODEGRADABLE LIPIDS AND FORMULATIONS FOR INTRAMUSCULAR, IN VITRO, AND EX VIVO TRANSFECTION OF MRNA

#28
20240182431
2024-06-06

NEW CONTRAST AGENT FOR USE IN MAGNETIC RESONANCE IMAGING

#29
20240174622
2024-05-30

COMPOUND AND RADIOACTIVE LABELING COMPOUND

#30
20240132454
2024-04-25

PROCESS FOR PRODUCING HEXAHYDRO 1,3,5-TRINITRO-1,3,5-TRIAZINE AND OCTAHYDRO-1,3,5,7-TETRANITRO-1,3,5,7-TETRAZOCINE

#31
20240108607
2024-04-04

METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF

#32
20240091389
2024-03-21

Compound targeting prostate specific membrane antigen, and preparation method and application thereof

#33
20240082438
2024-03-14

Bifunctional chelators and conjugates

#34
20240051928
2024-02-15

Bifunctional chelators and conjugates

#35
20240025866
2024-01-25

SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS

#36
20240018110
2024-01-18

RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN

#37
20240010623
2024-01-11

SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS

#38
20240010606
2024-01-11

FUMARATE DERIVATIVES AND THEIR MEDICAL USE

#39
20230416209
2023-12-28

COMPOUNDS AND METHODS TO TARGET GLUCOSE-STIMULATED PHOSPHOHISTIDINE SIGNALING AND ESOPHAGEAL CANCER GROWTH

#40
20230391735
2023-12-07

Manufacturing process for preparing gadoteridol

#41
20230356105
2023-11-09

TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR

#42
20230348405
2023-11-02

PSMA-TARGETING COMPOUNDS AND USES THEREOF

#43
20230330272
2023-10-19

COMPOUND AND MRI CONTRAST AGENT CONTAINING SAME

#44
20230295227
2023-09-21

COMPOUNDS FOR USE IN DIAGNOSIS AND/OR MONITORING OF FIBROSIS

#45
20230248851
2023-08-10

PROCEDURE FOR OBTAINING GADOTERATE MEGLUMINE FROM HIGH-PURITY TETRAXETAN (DOTA) AND ITS USE IN THE PREPARATION OF INJECTABLE GALENICAL FORMULATIONS

#46
20230183192
2023-06-15

NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR TREATING OR PREVENTING NEURAL DAMAGE, NEURAL DISEASE, OR DEVELOPMENTAL DISORDER THROUGH PROMOTING PROLIFERATION, DIFFERENTIATION, AND/OR REGENERATION OF NEURAL CELLS

#47
20230131121
2023-04-27

BRANCHED DISCRETE PEG CONSTRUCTS

#48
20230122957
2023-04-20

PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY

#49
20230114807
2023-04-13

RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN

#50
20230113481
2023-04-13

NEW GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING

#51
20230040042
2023-02-09

Manufacturing of protected DO3A

#52
20230015736
2023-01-19

PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER

#53
20220403051
2022-12-22

A DOTA binding chimeric antigen receptor for cellular therapy

#54
20220396549
2022-12-15

SMALL MOLECULE INHIBITORS OF THE MCL-1 ONCOPROTEIN AND USES THEROF

#55
20220259698
2022-08-18

METHOD FOR SYNTHESIZING ZIRCONIUM COMPLEX

#56
20220259161
2022-08-18

PSMA-targeting compounds and uses thereof

#57
20220259160
2022-08-18

METHOD FOR PRODUCING RADIOACTIVE METAL COMPLEX

#58
20220220085
2022-07-14

METHODS FOR PREPARING PSMA CONJUGATES

#59
20220143230
2022-05-12

Bifunctional do2pa derivatives, chelates with metallic cations and use thereof

#60
20220135529
2022-05-05

METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

#61
20220125923
2022-04-28

NOVEL AZOBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THERAPEUTIC TREATMENT ASSOCIATED WITH IONIZING RADIATIONS

#62
20220054664
2022-02-24

PHARMACOKINETIC ENHANCEMENTS OF BIFUNCTIONAL CHELATES AND USES THEREOF

#63
20220048872
2022-02-17

PSMA targeted fluorescent agents for image guided surgery

#64
20220024882
2022-01-27

NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF

#65
20210380542
2021-12-09

NOVEL PROCESS FOR THE PREPARATION OF MACROCYCLIC CHELANT 2,2',2''-(10-(2-HYDROXYPROPYL)-1,4,7,10-TETRA AZACYCLODODECANE-1,4,7-TRIYL) TRIACETIC ACID AND IT'S COMPLEXES WITH PARAMAGNETIC METAL IONS

#66
20210338851
2021-11-04

Radiolabeled compounds targeting the prostate-specific membrane antigen

#67
20210284614
2021-09-16

Method for manufacturing calteridol

#68
20210283279
2021-09-16

Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer

#69
20210283278
2021-09-16

Chiral cyclen compounds and their uses

#70
20210276961
2021-09-09

METHOD FOR MANUFACTURING CALCOBUTROL

#71
20210260195
2021-08-26

CONJUGATED LIPOMERS AND USES THEREOF

#72
20210221798
2021-07-22

HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING

#73
20210188787
2021-06-24

DOTA COMPOUNDS AND USES THEREOF

#74
20210179568
2021-06-17

Hydrolysis method for tert-butyl ester in gadolinium-based contrast agent

#75
20210177996
2021-06-17

Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer

#76
20210170058
2021-06-10

Modified antibody and radioactive metal-labelled antibody

#77
20210052748
2021-02-25

Compound, antiinflammatory drug comprising the compound and cyclooxygenase-2 inhibitor comprising the compound

#78
20210024500
2021-01-28

Dimeric contrast agents

#79
20210023264
2021-01-28

Use of immune modulators to improve nerve regeneration

#80
20210015802
2021-01-21

METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF

#81
20210009534
2021-01-14

Method for producing the crystalline form of modification a of calcobutrol

#82
20200385358
2020-12-10

Method for producing calcobutrol

#83
20200353104
2020-11-12

Gadolinium chelate compounds for use in magnetic resonance imaging

#84
20200347023
2020-11-05

Method for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

#85
20200331893
2020-10-22

DIMERIC CONTRAST AGENTS

#86
20200325108
2020-10-15

Contrast agents

#87
20200317612
2020-10-08

Branched Discrete PEG Constructs

#88
20200297876
2020-09-24

PSMA ligands for imaging and endoradiotherapy

#89
20200290982
2020-09-17

METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

#90
20200283420
2020-09-10

High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging

#91
20200270218
2020-08-27

Sensors for detection of negatively charged phosphate-containing membranes and membrane components

#92
20200231554
2020-07-23

Lipophilic macrocyclic ligands, complexes thereof, and uses of same

#93
20200216402
2020-07-09

PSMA targeted fluorescent agents for image guided surgery

#94
20200181098
2020-06-11

Gadobutrol intermediate and gadobutrol production method using same

#95
20200155713
2020-05-21

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

#96
20200140610
2020-05-07

CATALYSTS

#97
20200109124
2020-04-09

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

#98
20200038527
2020-02-06

Bifunctional do2pa derivatives, chelates with metallic cations and use thereof

#99
20200030291
2020-01-30

20-HETE receptor (GPR75) antagonists and methods of use

#100
20200017453
2020-01-16

Dimeric contrast agents

#101
20190388569
2019-12-26

Multifunctional chelators, complexes, and compositions thereof, and methods of using same

#102
20190374660
2019-12-12

Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer

#103
20190345142
2019-11-14

Dimeric contrast agents

#104
20190336622
2019-11-07

LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#105
20190210979
2019-07-11

Method for producing the crystalline form of modification a of calcobutrol

#106
20190167819
2019-06-06

Contrast agents

#107
20190167795
2019-06-06

Conjugated lipomers and uses thereof

#108
20190153620
2019-05-23

LIBRARIES OF DIVERSE MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME

#109
20190134240
2019-05-09

Dimerization strategies and compounds for molecular imaging and/or radioimmunotherapy

#110
20190134239
2019-05-09

Pre-targeting strategies for molecular imaging and/or radioimmunotherapy

#111
20190092895
2019-03-28

Energetic compounds and compositions

#112
20190083659
2019-03-21

Gadolinium chelate compounds for use in magnetic resonance imaging

#113
20190070221
2019-03-07

Methods to mobilize tissue resident cells for adoptive t cell therapy

#114
20190060491
2019-02-28

Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

#115
20190055352
2019-02-21

Catalysts

#116
20190038785
2019-02-07

Compounds, compositions and associated methods using zirconium-89 in immuno-positron emission tomography

#117
20190030194
2019-01-31

Pharmacokinetic enhancements of bifunctional chelates and uses thereof

#118
20190008988
2019-01-10

Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

#119
20180370925
2018-12-27

DOTA synthesis

#120
20180362511
2018-12-20

Dimeric contrast agents

#121
20180362476
2018-12-20

Contrast agents

#122
20180354915
2018-12-13

Method for preparing anti-heart-failure medicine LCZ696

#123
20180339071
2018-11-29

Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer

#124
20180244635
2018-08-30

Process for the preparation of xylene linked cyclam compounds

#125
20180208554
2018-07-26

Small molecule inhibitors of the MCL-1 oncoprotein and uses thereof

#126
20180169274
2018-06-21

Gadolinium chelate compounds for use in magnetic resonance imaging

#127
20180111893
2018-04-26

Substituted polycationic multi-quaternary ammonium salts as antimicrobial agents

#128
20180105537
2018-04-19

Preparation of high-purity gadobutrol

#129
20180085478
2018-03-29

Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents

#130
20180009767
2018-01-11

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

#131
20170342038
2017-11-30

Method for preparing gadobutrol

#132
20170340757
2017-11-30

Targeted contrast agents comprising a hydrazide functional group

#133
20170326261
2017-11-16

BIFUNCTIONAL do2pa DERIVATIVES, CHELATES WITH METALLIC CATIONS AND USE THEREOF

#134
20170313656
2017-11-02

Branched discrete PEG constructs

#135
20170283384
2017-10-05

PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY

#136
20170266304
2017-09-21

Metal complex formulations

#137
20170260148
2017-09-14

Method for preparing calcobutrol

#138
20170240582
2017-08-24

1,4,7,10-tetrazacyclododecane based agents to target bacteria and its use

#139
20170226270
2017-08-10

Energetic compounds and compositions

#140
20170210848
2017-07-27

Catalysts

#141
20170210714
2017-07-27

Macrocyclic complexes, their process of preparation and use as PET imaging agents

#142
20170081298
2017-03-23

Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy

#143
20170029386
2017-02-02

N-alkoxyamide conjugates as imaging agents

#144
20170007726
2017-01-12

Process for purifying 1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid

#145
20160331849
2016-11-17

Gadolinium complex comprising DO3A-tranexamic acid conjugate

#146
20160304473
2016-10-20

Excimer forming compounds

#147
20160235870
2016-08-18

Multifunctional chelators, complexes, and compositions thereof, and methods of using same

#148
20160228587
2016-08-11

LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER

#149
20160206740
2016-07-21

Conjugated lipomers and uses thereof

#150
20160194690
2016-07-07

Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency

#151
20160185803
2016-06-30

Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates

#152
20160185737
2016-06-30

N-alkoxyamide conjugates as imaging agents

#153
20160137669
2016-05-19

Preparation of Grignard reagents using a fluidized bed

#154
20160024030
2016-01-28

Process for producing 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid and complexes thereof

#155
20160022844
2016-01-28

Tetrahydroxamate chelators of zirconium89 and niobium90 for use in diagnostic applications

#156
20150343094
2015-12-03

Compositions and methods for in vivo imaging

#157
20150291538
2015-10-15

Macrocyclic Compositions And Metal Complexes For Bioimaging And Biomedical Applications

#158
20150259304
2015-09-17

Process for the preparation of macrocyclic polyazacarboxylate ligands and chelates

#159
20150246144
2015-09-03

Labeled inhibitors of prostate specific membrane antigen (PSMA) biological evaluation, and use of imaging agents

#160
20150104387
2015-04-16

PSMA-targeting compounds and uses thereof

#161
20150094465
2015-04-02

N-alkoxyamide conjugates as imaging agents

#162
20150080567
2015-03-19

Method to Produce and Scale-Up Cocrystals and Salts Via Resonant Acoustic Mixing

#163
20150078998
2015-03-19

Radiolabeled prostate specific membrane antigen inhibitors

#164
20150078997
2015-03-19

N-alkoxyamide conjugates as imaging agents

#165
20150071863
2015-03-12

Lanthanoid complex capsule and particle contrast agents, methods of making and using thereof

#166
20150005319
2015-01-01

Macrocyclic compounds for modulating IL-17

#167
20140323719
2014-10-30

Process for the purification of polyaminocarboxylates

#168
20140323717
2014-10-30

Methods for preparing functional tetraazacycloalkane compounds using a specific cyclic bisaminal compound

#169
20140275521
2014-09-18

Aza metal complexes

#170
20140243397
2014-08-28

CXCR4 inhibiting carriers for nucleic acid delivery

#171
20140187527
2014-07-03

Macrocyclic compounds and metal complexes for bioimaging and biomedical applications

#172
20140179015
2014-06-26

Responsive luminescent lathanide complexes

#173
20140107325
2014-04-17

Preparation of high-purity gadobutrol

#174
20130315822
2013-11-28

N-alkoxyamide conjugates as imaging agents

#175
20130231475
2013-09-05

MRI contrast agent having gadolinium complex

#176
20130224874
2013-08-29

Phosphorescent meso-unsubstituted metallo-tetrabenzoporphyrin probe molecules for measuring oxygen and imaging methods

#177
20130202536
2013-08-08

Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency

#178
20130156851
2013-06-20

Lipomacrocycles and uses thereof

#179
20130052130
2013-02-28

Branched Discreet PEG Constructs

#180
20130034494
2013-02-07

Radiolabeled prostate specific membrane antigen inhibitors

#181
20130004423
2013-01-03

Polyazamacrocyclic compound, and a production method and a biomedical use therefor

#182
20120328514
2012-12-27

N-alkoxyamide conjugates as imaging agents

#183
20120318750
2012-12-20

METHODS AND COMPOSITIONS FOR COMPLEX BINDING OF METAL IONS

#184
20120309962
2012-12-06

Process for the preparation of calcobutrol

#185
20120294809
2012-11-22

Lanthanoid complex capsule and particle contrast agents, methods of making and using thereof

#186
20120277421
2012-11-01

Metal complexes of tetraazamacrocycle derivatives

#187
20120276001
2012-11-01

Bifunctional polyazamacrocyclic chelating agents

#188
20120251560
2012-10-04

Conjugated lipomers and uses thereof

#189
20120231297
2012-09-13

Lubricant composition, fluorine-based compound, and use thereof

#190
20120219495
2012-08-30

Tetraaza macrocyclic compound, preparation method thereof and use thereof

#191
20120149896
2012-06-14

Method for separation of HMX and RDX

#192
20120093735
2012-04-19

Complex compound and MRI probe made of same

#193
20120029177
2012-02-02

HETEROCYCLE-AMINO ACID DERIVATIVES FOR TARGETING CANCER TISSUE AND RADIOACTIVE OR NON-RADIOACTIVE LABELED COMPOUNDS THEREOF

#194
20120009121
2012-01-12

PSMA-targeting compounds and uses thereof

#195
20110294044
2011-12-01

Materials and their use for the electrocatalytic evolution or uptake of H

#196
20110287558
2011-11-24

Responsive luminescent lanthanide complexes

#197
20110268663
2011-11-03

Intravascular contrast agents

#198
20110230662
2011-09-22

Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging

#199
20110177002
2011-07-21

CYLIC POLYAMINES FOR BINDING PHOSPHATIDYLSERINE

#200
20110165089
2011-07-07

Complex Compound and MRI Probe Made of Same

#201
20110064657
2011-03-17

Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents

#202
20110054066
2011-03-03

Use of polymerizable macrocyclic polyethers and macrocyclic heteroanalogous polyethers in dental materials

#203
20110038805
2011-02-17

COMPOUNDS COMPRISING PARAMAGNETIC CHELATES ARRANGED AROUND A CENTRAL CORE AND THEIR USE IN MAGNETO RESONANCE IMAGING AND SPECTROSCOPY

#204
20110028713
2011-02-03

AZA compounds and production method thereof, and metal complexes as MRI contrast agents

#205
20100240638
2010-09-23

Organic Compounds and their uses

#206
20100190967
2010-07-29

Method of dynamic nuclear polarisation (DNP) and compounds and compositions for use in the method

#207
20100179116
2010-07-15

Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof

#208
20100152099
2010-06-17

Macrocyclic compounds for inhibition of tumor necrosis factor alpha

#209
20100150836
2010-06-17

Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging

#210
20100143250
2010-06-10

COMPOUNDS FOR THE DIAGNOSIS OF APOPTOSIS

#211
20100081799
2010-04-01

Chelating Agent

#212
20100055043
2010-03-04

Poly-Halo Metal X-ray Contrast Agents

#213
20100028936
2010-02-04

Detection of cancer cells in vitro using sigma-2 receptor ligands as radiotracers

#214
20090297454
2009-12-03

Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use

#215
20090275727
2009-11-05

Peptide turn mimetics

#216
20090252676
2009-10-08

N-alkoxyamide conjugates as imaging agents

#217
20090238768
2009-09-24

MULTIMERIC MAGNETIC RESONANCE CONTRAST AGENTS

#218
20090216011
2009-08-27

Synthesis of cyclen derivatives

#219
20090202521
2009-08-13

Bifunctional polyazamacrocyclic chelating agents

#220
20090169479
2009-07-02

Compounds comprising short aminoalcohol chains and metal complexes for medical imaging

#221
20090156801
2009-06-18

Biomolecule labeling reactants based on azacycloalkanes and conjugates derived thereof

#222
20090136417
2009-05-28

GLYCEROL ESTER DERIVATIVE HAVING METAL CHELATE STRUCTURE

#223
20090068248
2009-03-12

Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same

#224
20090041663
2009-02-12

Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors

#225
20090036674
2009-02-05

Metal complexes of tetraazamacrocycle derivatives

#226
20080293711
2008-11-27

Chemokine receptor modulators

#227
20080287454
2008-11-20

CXCR4 antagonists

#228
20080188423
2008-08-07

PI-3 kinase inhibitor prodrugs

#229
20080159954
2008-07-03

Metal chelates having a perfluorinated PEG radical, processes for their preparation, and their use

#230
20080145311
2008-06-19

Chelating agents with lipophilic carriers

#231
20080124270
2008-05-29

Compounds Useful as Metal Chelators

#232
20080107606
2008-05-08

Bifunctional chelators for sequestering lanthanides

#233
20080107599
2008-05-08

Radiolabelled benzamide analogues, their synthesis and use in diagnostic imaging

#234
20080087887
2008-04-17

Compound for molecular electronic device

#235
20080058382
2008-03-06

Polyamine compounds

#236
20080038750
2008-02-14

Multivalent chelators containing a scaffold structure for modifying and organizing of target molecules

#237
20070244316
2007-10-18

Optically pure and enriched isomers of chelating ligands and contrast agents

#238
20070237721
2007-10-11

Targeted MR imaging agents

#239
20070202047
2007-08-30

Polyamine-substituted ligands for use as contrast agents

#240
20070189969
2007-08-16

Perfluoroalkyl-containing complexes, process for their production as well as their use

#241
20070167615
2007-07-19

Macrocyclic oligonucleotide labeling reactants and conjugates derived thereof

#242
20070104645
2007-05-10

Chelate based scaffolds in tumor targeting

#243
20070098643
2007-05-03

Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates

#244
20070060591
2007-03-15

Chemokine receptor binding heterocyclic compounds

#245
20070020183
2007-01-25

Perfluoroalkyl-containing complexes, process for their production as well as their use

#246
20070014721
2007-01-18

Hydrazide conjugates as imaging agents

#247
20070009442
2007-01-11

Macrocyclic metal complexes and their use for the production of conjugates with biomolecules

#248
20060281185
2006-12-14

Detection of analytes in aqueous environments

#249
20060275217
2006-12-07

Chemical exchange saturation transfer contrast agents

#250
20060252673
2006-11-09

Histogranin-like peptides and non-peptides, processes for their preparation and uses thereof

#251
20060217548
2006-09-28

Method of preparing cis-8b-methyldecahydro-2a,4a,6a,8a-tetraazacyclopenta[fg]acenaphthylene, cis-decahydro-2a,4a,6a,8a-tetraazacyclopenta[fg]acenaphthylene, cyclene and functionalised cyclenes

#252
20060165600
2006-07-27

Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same

#253
20060155120
2006-07-13

Optically pure and enriched isomers of chelating ligands and contrast agents

#254
20060154989
2006-07-13

Trimeric, macrocyclically substituted halo-benzene derivatives

#255
20060120965
2006-06-08

Trimeric, macrocyclically substituted aminoisophthalic acid-halo-benzene derivatives

#256
20060078503
2006-04-13

1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them

#257
20060069249
2006-03-30

16-member ring metal chelate

#258
20060069129
2006-03-30

Chemokine receptor binding heterocyclic compounds

#259
20060057071
2006-03-16

Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as MRI contrast agents

#260
20050250743
2005-11-10

Ammonium salts of inositol hexaphosphate, and uses thereof

#261
20050233953
2005-10-20

Histogranin-like peptides, processes for their preparation and uses thereof

#262
20050203173
2005-09-15

PI-3 kinase inhibitor prodrugs

#263
20050154005
2005-07-14

Methods to modulate conditions mediated by the CXCR4 receptor

#264
20050148566
2005-07-07

Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same

#265
20050147563
2005-07-07

Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis

#266
20050130949
2005-06-16

Cyclic polyamine compounds for cancer therapy

#267
20050107398
2005-05-19

Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors

#268
20050043366
2005-02-24

Polyamine compounds for treating chemokine receptor mediated diseases

#269
20050033106
2005-02-10

Synthesis of tris N-alkylated 1,4,7,10-tetraazacyclododecanes